Literature DB >> 18034997

Microalbuminuria in Thai essential hypertensive patients.

P Buranakitjaroen1, M Phoojaroenchanachai, S Saravich.   

Abstract

Essential hypertensive patients (176 males and 329 females), aged 58.0+/-11.2 years were enrolled in a cross-sectional study conducted from February to March 2006 to investigate the prevalence and risk factors for microalbuminuria in hypertensive patients attending the Outpatient Department of Siriraj Hospital, Bangkok, Thailand. Macroalbuminuria was detected in 11 (2.2%) patients and microalbuminuria in 94 (18.6%) patients. Only male aged>or=45 years or female aged>or=55 years correlated significantly with a high occurrence of microalbuminuria, while calcium channel blocker and statin users were protected against microalbuminuria. The presence of microalbuminuria was not associated with age>or=60 years, male gender, current/previous smokers, hypertension duration>or=10 years, lack of blood pressure normalization, metabolic syndrome, use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and multi-drug use. Risk factor recognition for microalbuminuria will enable physicians to identify cases that should be screened for microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034997     DOI: 10.1177/147323000703500612

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients.

Authors:  Pongsathorn Gojaseni; Angkana Phaopha; Worawon Chailimpamontree; Thaweepong Pajareya; Anutra Chittinandana
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

2.  Body mass index (BMI) is associated with microalbuminuria in Chinese hypertensive patients.

Authors:  Xinyu Liu; Yu Liu; Youming Chen; Yongqiang Li; Xiaofei Shao; Yan Liang; Bin Li; Harry Holthöfer; Guanjing Zhang; Hequn Zou
Journal:  Int J Environ Res Public Health       Date:  2015-02-10       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.